Anesthesia Combinations for Scoliosis Surgery
Trial Summary
What is the purpose of this trial?
Patients with Adolescent Idiopathic Scoliosis may need surgery to correct their scoliosis. General anesthesia is required for this surgery, and a multimodal analgesic regimen using combinations of opioid and non-opioid medications is the standard of care. The purpose of this study is to compare two combinations of total intravenous anesthetic medications in children with Adolescent Idiopathic Scoliosis having posterior spinal fusion surgery. Participants in the study will be randomly selected to receive either Propofol and Remifentanil or Propofol and Dexmedetomidine as their total intravenous anesthesia (TIVA). TIVA is favored over gas anesthesia because gas anesthesia can affect the neurological monitoring necessary for this surgery. The first combination (Propofol + Remifentanil) is the most common one used for this surgery at our institution, and the second combination (Propofol + Dexmedetomidine) is more commonly used in adult spine surgery. Though Dexmedetomidine is not approved for pediatric use by the FDA, it is widely used in pediatric patients for procedural sedation and surgical anesthesia in the US and worldwide. Both anesthetic combinations are used safely in adult and pediatric patients at our institution. Although remifentanil works fast and is an excellent pain medication during surgery, there are reports that it's use can cause increased pain sensitivity and greater need for narcotic pain medication after surgery. This phenomenon is known as opioid-induced hyperalgesia. The investigators hypothesize that avoiding the use of remifentanil in the TIVA by using dexmedetomidine could avoid OIH and thus result in superior postop pain control. Our study's primary goal is to measure the total opioid consumption on postoperative days (POD)# 0 and 1. Our secondary goals are to measure the pain scores on a visual analog scale (VAS) on POD# 0 and 1, measure the time it takes for participants to move their feet to command when surgery is done, and measure the time it takes for participants to be extubated when surgery is done. By comparing these measurements, the investigators hope to find out if there is any significant difference between the two TIVAs in terms of postop opioid requirements, pain scores, and time to wake up from anesthesia. The investigators hope that our study gives us more knowledge on how to better treat postoperative pain in children who have spine surgery to correct their
Will I have to stop taking my current medications?
The trial requires that you do not use serotonergic drugs, monoamine oxidase inhibitors (MAOI), or mixed agonist/antagonist opioid analgesics. If you are taking any of these, you may need to stop them to participate.
Is the combination of dexmedetomidine and remifentanil safe for scoliosis surgery?
Dexmedetomidine and remifentanil are used in scoliosis surgery to help with sedation and pain management. While remifentanil is effective, it may lead to increased pain and opioid use after surgery. Dexmedetomidine is used to maintain stability during surgery, but specific safety data for these drugs in scoliosis surgery is limited.12345
How is the drug combination of Dexmedetomidine and Remifentanil unique for scoliosis surgery?
This drug combination is unique because it allows for sedation and pain relief while maintaining ventilatory stability during the wake-up test, a critical part of scoliosis surgery to check for nerve function. Dexmedetomidine helps reduce the need for higher doses of other anesthetics, potentially minimizing their side effects, while Remifentanil provides short-acting pain control.12467
Research Team
Glenn Tan, M.D.
Principal Investigator
Cedars-Sinai Medical Center
Eligibility Criteria
This trial is for adolescents aged 12-18 with Adolescent Idiopathic Scoliosis, classified as ASA Class 1 or 2, who are undergoing posterior spinal fusion surgery. They must be matched by age, sex, and number of vertebral levels fused.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo posterior spinal fusion surgery with either Propofol + Remifentanil or Propofol + Dexmedetomidine as their total intravenous anesthesia
Postoperative Monitoring
Participants' opioid consumption and pain scores are measured on postoperative days 0 and 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Dexmedetomidine (Sedative)
- Remifentanil (Opioid)
Dexmedetomidine is already approved in Canada, Japan for the following indications:
- Sedation in intensive care settings
- Procedural sedation
- Sedation in intensive care settings
- Procedural sedation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cedars-Sinai Medical Center
Lead Sponsor
David E. Cohen
Cedars-Sinai Medical Center
Chief Medical Officer
MD and PhD in Physiology and Biophysics from Harvard University
Peter L. Slavin
Cedars-Sinai Medical Center
Chief Executive Officer
MD from Harvard Medical School, MBA from Harvard Business School